Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Tamar Tchkonia
Mayo Clinic Rochester, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cenexys, Inc. (nka Unity Biotechnology)
Other : Total IP royalties, through Mayo Clinic
Please see attached.
Effect of Aging on Preadipocyte Differentiation
Aging is the leading risk factor for most of the chronic diseases that account for the bulk of morbidity, mortality, and health costs. It may be feasible to delay age-related diseases as a group by targeting an aging mechanism, cellular senescence. Senescent cells are cells that have stopped dividing and that cause tissue dysfunction. They accumulate with aging and age-related chronic diseases. We discovered that removing senescent cells enhances healthy lifespan in genetically modified mice. Our goal now is to develop drugs that selectively target senescent cells -senolytic agents. We developed prototype senolytic agents and discovered they ameliorate a range of senescence-related disorders in animals. We will now determine how they kill senescent cells in order to make further senolytic drugs. We will characterize the types of senescent cells they kill so we can develop agents that work on the most damaging senescent cells in specific tissues. This will enable us develop agents for treating particular age-related disorders. The impact of senolytic agents on lifespan will be tested in animals. Development of drugs that eliminate senescent cells is of potentially profound significance. It is possible that senolytic agents could transform management of multiple age-related disorders.
Filed on May 15, 2019.
Tell us what you know about Tamar Tchkonia's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Tamar Tchkonia”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Tamar Tchkonia | Mayo Clinic Rochester | Conflict of Interest | Cenexys, Inc. (nka Unity Biotechnology) | $300,000 - $349,999 |
| Tamar Tchkonia | Mayo Clinic Rochester | Conflict of Interest | Cenexys, Inc. (nka Unity Biotechnology | $150,000 - $199,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.